With the FDA’s recent approval of Guardant Health’s Shield blood test and Exact Sciences’ Cologuard Plus stool test, colorectal cancer (CRC) screening options are expanding beyond traditional colonoscopy. While these tests offer convenience and could boost screening rates, concerns remain about their effectiveness in detecting precancerous lesions and preventing CRC compared to colonoscopy.
Are these innovations a breakthrough or a compromise? Dive deeper into the debate, expert insights, and the latest research on CRC screening advancements.